Yes, heparin is definitively used in myocardial infarction and acute coronary syndrome.
Parenteral anticoagulation with heparin (unfractionated heparin or low-molecular-weight heparin) is recommended for all patients with ACS, regardless of the initial treatment strategy, to treat the underlying coronary atherothrombosis and reduce the risk of recurrent major adverse cardiovascular events. 1
Core Recommendations by ACS Type
For NSTE-ACS (Unstable Angina/Non-STEMI)
- Intravenous unfractionated heparin (UFH) is useful to reduce ischemic events (Class I recommendation) 1
- Enoxaparin or fondaparinux are recommended alternatives to UFH when an early invasive approach is not anticipated 1
- Heparin combined with aspirin reduces short-term rates of cardiovascular death and MI by approximately 30% over aspirin alone 2
Dosing for UFH: Loading dose 60 IU/kg (max 4000 IU), with initial infusion 12 IU/kg/h (max 1000 IU/h) adjusted to therapeutic aPTT range of 60-80 seconds 1
For STEMI
When treated with fibrinolytic therapy:
- Parenteral anticoagulation should be continued for the duration of hospital stay (maximum 8 days) or until revascularization 1
- Enoxaparin is the recommended anticoagulant (Class I, Level A) 1
- Fondaparinux is a recommended alternative (Class I, Level B-R) 1
When undergoing PCI:
- Intravenous UFH is useful to reduce ischemic events (Class I) 1
- Bivalirudin is useful as an alternative to UFH to reduce mortality and bleeding (Class I, Level B-R) 1
Critical Timing and Context
Heparin is never used as sole therapy in modern ACS management. 2 It is always combined with:
- Aspirin in all potentially eligible patients with acute myocardial ischemia
- Thrombolytic therapy for evolving MI
- Platelet GP IIb/IIIa antagonists for unstable angina
- During high-risk coronary angioplasty
Anticoagulation must be initiated upstream (at the time of diagnosis and prior to coronary angiography if planned) and continued to support PCI or other reperfusion therapy 1.
Important Caveats and Pitfalls
Bleeding Risk Management
When combined with thrombolytic agents or GP IIb/IIIa antagonists, heparin in full doses increases bleeding risk, and the dose is usually reduced in these settings 2.
Post-PCI Heparin Use
Avoid routine post-PCI heparin continuation without specific indications. Recent evidence shows post-PCI anticoagulation with UFH was associated with increased bleeding (4.75% vs 2.52%, adjusted HR 1.69) without reducing cardiovascular events 3. Current guidelines discourage anticoagulation after PCI without specific indications 3.
Do Not Switch Between Heparin Types
Avoid crossover between UFH and LMWH during treatment - interchanging between these agents is associated with worse outcomes than continued therapy with either form 4. Each LMWH has a unique pharmacodynamic profile and they are not interchangeable 5.
Monitoring Requirements
- Monitor platelet counts before and periodically during therapy (thrombocytopenia occurs in up to 30% of patients) 6
- If platelet count falls below 100,000/mm³, promptly discontinue heparin and evaluate for heparin-induced thrombocytopenia (HIT) 6
- Adjust UFH dose based on frequent coagulation tests (aPTT) 6
Special Populations
Renal dysfunction: Reduce enoxaparin dose to 1 mg/kg daily if CrCl <30 mL/min 1. Fondaparinux is contraindicated if CrCl <30 mL/min 1.
Elderly (≥75 years) with fibrinolytic therapy: No bolus enoxaparin; use 0.75 mg/kg subcutaneous every 12 hours (maximum 75 mg for first 2 doses) 1.
Specific Contraindication
Fondaparinux should not be used to support PCI due to risk of catheter thrombosis (0.9% vs 0.3% with enoxaparin) 1.
Evidence Quality
The most recent 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines 1 provide the strongest recommendations, superseding older 2001 AHA guidance 2. The evidence base includes multiple randomized controlled trials showing heparin reduces MI risk (RR 0.40,95% CI 0.25-0.63) 7, though with increased minor bleeding (RR 6.80) 7.